High Resolution Melting Curve Assay for Detecting rs12979860 IL28B Polymorphisms Involved in Response of Iranian Patients to Chronic Hepatitis C Treatment |
Fateh, Abolfazl
(Department of Virology, School of Public Health, Tehran University of Medical Sciences)
Aghasadeghi, Mohammad Reza (Department of Hepatitis and AIDS, Pasteur Institute of Iran) Keyvani, Hossein (Departments of Virology, Iran University of Medical Sciences) Mollaie, Hamid Reza (Departments of Virology, Iran University of Medical Sciences) Yari, Shamsi (Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran) Tasbiti, Ali Reza Hadizade (Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran) Ghazanfari, Morteza (Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran) Monavari, Seyed Hamid Reza (Departments of Virology, Iran University of Medical Sciences) |
1 | Sharafi H, Pouryasin A, Alavian SM, et al (2012). Development and validation of a simple, rapid and inexpensive PCR-RFLP Method for genotyping of common IL28B polymorphisms: A useful pharmacogenetic tool for prediction of hepatitis C treatment response. Hepat Mon, 12, 190-5. |
2 | Shi X, Pan Y, Wang M, et al (2012). IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One, 7, 37054. DOI |
3 | Su CH, Lin Y, Cai L (2013). Genetic factors, viral infection, other factors and liver cancer: an update on current progress. Asian Pac J Cancer Prev, 14, 4953-60. DOI ScienceOn |
4 | Suppiah V, Moldovan M, Ahlenstiel G, et al (2009). IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet, 41, 1100-4. DOI ScienceOn |
5 | Thomas DL, Thio CL, Martin MP, et al (2009). Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 461, 798-801. DOI |
6 | Tsubota A, Kiyotaka F, Yoshihisa N, et al (2011). Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol, 17, 419-432. DOI |
7 | Viazov S, Kuzin S, Paladi N, et al (1997). Hepatitis C virus genotypes in different regions of the former Soviet Union (Russia, Belarus, Moldova, and Uzbekistan). J Med Virol, 53, 36-40. DOI |
8 | Wohnsland A, Hofmann WP, Sarrazin C (2007). Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev, 20, 23-38. DOI |
9 | Yang JD, Roberts LR (2010). Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol, 7, 448-58. DOI |
10 | Zali MR, Mayumi M, Raoufi M, et al (2000). Hepatitis C virus genotypes in the Islamic Republic of Iran: a preliminary study. East Mediterr Health J, 6, 372-7. |
11 | Zekri AR, Salama H, Medhat E, et al (2014). IL28B rs12979860 Gene polymorphism in Egyptian patients with chronic liver disease infected with HCV. Asian Pac J Cancer Prev, 15, 7213-8. DOI |
12 | Altuglu I, Soyler I, Ozacar T, et al (2008). Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis, 12, 239-44. DOI |
13 | Afshar RM, Mollaie HR (2012). Detection of HBV resistance to lamivudine in patients with chronic hepatitis B using zip nucleic acid probes in Kerman, southeast of Iran. Asian Pac J Cancer Prev, 13, 3657-61. DOI ScienceOn |
14 | Akkarathamrongsin S, Thong VD, Payungporn S, et al (2014). IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. J Med Virol, 86, 1482-90. DOI |
15 | Alavian SM, Tabatabaei SV, Keshvari M, et al (2010). Peginterferon alpha-2a and ribavirin treatment of patientswith haemophilia and hepatitis C virus infection: a singlecentre study of 367 cases. Liver Int, 30, 1173-80. DOI |
16 | Antaki N, Craxi A, Kamal S, et al (2010). Theneglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int, 30, 342-55. DOI |
17 | Chen X, Sullivan PF (2003). Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput. Pharmacogenomics J, 3, 77-96. DOI |
18 | Asselah T, Bieche I, Paradis V, et al (2007). Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis, 27, 13-27. DOI |
19 | Balagopal A, Thomas DL, Thio CL (2010). IL28B and the control of hepatitis C virus infection. Gastroenterology, 139, 1865-76. DOI |
20 | Beinhardt S, Rutter K, Stattermayer AF, Ferenci P (2013). Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus. Clin Infect Dis, 56, 118-122. DOI |
21 | Dai CY, Huang JF, Hsieh MY, et al (2009). Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol, 50, 712-8. DOI |
22 | Domagalski K, Pawlowska M, Tretyn A, et al (2013). Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. Eur J Clin Microbiol Infect Dis, 32, 745-54. DOI |
23 | Eslam M, Leung R, Romero-Gomez M, et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol, 61, 235-41. DOI |
24 | European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2014. From: http://www.easl.eu/_newsroom/latest-news/easlrecommendations-on-treatment-of-hepatitis-c-2014 |
25 | Falleti E, Bitetto D, Fabris C, et al (2011). Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol, 31, 891-9. DOI |
26 | Grebely J, Petoumenos K, Hellard M, et al (2010). Potential role for interleukin-28B genotype in treatment decisionmaking in recent hepatitis C virus infection. Hepatology, 52, 1216-24. DOI |
27 | Ge D, Fellay J, Thompson AJ, et al (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 461, 399-401 DOI |
28 | Ghany MG, Nelson DR, Strader DB, et al (2011). American association for study of liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 54, 1433-44. DOI |
29 | Ghany MG, Strader DB, Thomas DL, Seeff LB (2009). Diagnosis, management, and treatment of hepatitis C: an update. Hepatology, 49, 1335-74. DOI |
30 | Kau A, Vermehren J, Sarrazin C (2008). Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol, 49, 634-51. DOI |
31 | Keyvani H, Alizadeh AH, Alavian SM, et al (2007). Distribution frequency of hepatitis C virus genotypes in 2231 patients in Iran. Hepatol Res, 37, 101-3. DOI |
32 | Keyvani H, Fazlalipour M, Monavari SH, et al (2012). Hepatitis C virus--proteins, diagnosis, treatment and new approaches for vaccine development. Asian Pac J Cancer Prev, 13, 5931-49. |
33 | Mangia A, Thompson AJ, Santoro R, et al (2010). An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology, 139, 821-7. DOI ScienceOn |
34 | Martinez-Gomez LE, Chavez-Tapia NC, Burguete-Garcia AI, et al (2012). IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population. Ann Hepatol, 11, 876-81. |
35 | Poon KS, Ho SS, Tang JW, et al (2012). Targeting both rs12979860 and rs8099917 polymorphisms with a singletube high-resolution melting assay for IL28b genotyping. J Clin Microbiol, 50, 3353-5. DOI |
36 | Melis R, Fauron C, McMillin G, et al (2011). Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. J Mol Diagn, 13, 446-51. DOI |
37 | Moghaddam A, Melum E, Reinton N, et al (2011). IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology, 53, 746-54. DOI |
38 | Namazee N, Sali S, Asadi S, et al (2012). Real response to therapy in chronic hepatitis C virus patients: a study from Iran. Hepat Mon, 12, 6151. |
39 | Pourhoseingholi MA, Fazeli Z, Zali MR, et al (2010). Burden of hepatocellular carcinoma in Iran; Bayesian projection and trend analysis. Asian Pac J Cancer Prev, 11, 859-62. |
40 | Rauch A, Kutalik Z, Descombes P, et al (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 138, 1338-45. DOI ScienceOn |
41 | Sajid A, Ayaz A, Raham Sh, et al. Genotyping of HCV RNA Reveals That 3a Is the Most Prevalent Genotype in Mardan, Pakistan. Advances in Virology, 2014, 1-5. |
42 | Samimi-Rad K, Nategh R, Malekzadeh R, et al (2004). Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol, 74, 246-52. DOI |
43 | Sarrazin C, Susser S, Doehring A, et al (2011). Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol, 54, 415-21. DOI |